|
Teva Pharmaceuticals: A Picture of Health |
|
| Jul 08, 2008 04:56 PM UTC |
|
Tracked Blogger
|
6/25 - "Teva Pharmaceuticals (TEVA) is an Israeli generic drug company. Teva’s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease...It seems investors are perceiving it as a “safer” play in the midst of turbulence. Don’t think that there isn’t any growth here though." "It is trading at a reasonable PEG ratio of 1.0 on next year’s earnings. Estimates have been ticking up as well, rising a penny to $2.70 per share for this year over the past 60 days. TEVA has also beaten estimates in each of the past four quarters by an average margin of 5.1%. We see the stock around $52 within 6-to-12 months." 
Read the rest of original post »
|
|||||||||||||||
|
3 Related Views
| ||||||||||||||||
|
| ||||||||||||||||
 N/A risk: moderate |
What Tiger Woods and Teva Pharmaceuticals Have in Common
6/17 - "Quoted from a recent interview on the WSJ’s Health Blog (link here), the Novartis CEO basically pulled a Rocco Mediate, Tiger’s 45 year old , nice-as-anything nemesis in the playoffs who just wouldn’t quit. Addressing a great performance by Teva (TEVA), the #1 generic drug manufacturer globally compared to Novartis’s Sandoz unit at #2, Novartis CEO, a la Rocco, said, “Teva is better tha...
|
|||||||||||||||
|
| ||||||||||||||||
|
N/A risk: conservative |
Downgrading Teva to Hold Following Failure of Copaxone Drug Trial
7/7 - "While we continue to believe that Teva remains the premier generic drug company for a host of reasons, including management’s excellent track record, its sizeable generic pipeline, the company’s competitive advantages (e.g., global supply chain), as well as its key branded product franchises, we downgraded Teva’s shares to Hold early this morning following the failed Copaxone 40 mg Phase...
|
|||||||||||||||
|
| ||||||||||||||||
|
N/A risk: conservative |
Adding Teva to Conviction Buy List; Positive Near-Term Catalysts Ahead
7/7 - "We are adding Teva to the Americas Conviction List following Monday’s ~9% pull-back (S&P 500 down ~1%) which eliminated ~ $3.4 billion in equity cap and has now placed shares near a 5-year low on P/E. While disappointing Copaxone 40mg (FORTE trial) phase III results tempers one source of potential upside, we see Azilect as the more important near-term driver to franchise value. Combinati...
|
|||||||||||||||
Add Comment
|
|
Parkinson's Disease has never been slowed by any drug in over 100 years since identified. Now TEVA has a new drug Azilect, that can do this. I agree that this is a very good company to take a chance on, especially with the recent drawback in the stock price. |
|
|
|
|||
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |
